Shenzhen Geno-Immune Medical Institute

Country

Ownership: Private

Established: 2015-04-28

Employees: -

Market Cap: -

Website

Clinical Trials

Combination Immunotherapy Targeting Melanoma

Phase 1

Recruiting

Conditions: Melanoma

Interventions: Biological: Antigen-specific CAR T, CTL and DCvac to treat melanoma.

First Posted Date: 2024-12-18

Last Posted Date: 2024-12-18

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 30

Registration Number: NCT06739226

Locations: 🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China

Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells

Phase 1

Recruiting

Conditions: Autoimmune Diseases

Interventions: Biological: fetal MSCs combined with 4SCAR T cells

First Posted Date: 2024-05-30

Last Posted Date: 2024-05-30

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 30

Registration Number: NCT06435897

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma or Plasmacytoma

Interventions: Biological: DC vaccines

First Posted Date: 2024-05-30

Last Posted Date: 2024-06-10

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT06435910

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇷🇺
The Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health, Vladivostok, Russian Federation

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Phase 1

Recruiting

Conditions: Multiple Myeloma
Plasmacytoma

Interventions: Biological: CAR-T cells

First Posted Date: 2024-05-24

Last Posted Date: 2024-06-10

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 20

Registration Number: NCT06429150

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇷🇺
Hematologist of the Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health, Vladivostok, Russian Federation

Universal CAR-T Cells Targeting Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma in Remission

Interventions: Biological: MM-specific universal CAR T cells

First Posted Date: 2023-08-23

Last Posted Date: 2023-10-12

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 20

Registration Number: NCT06006741

Locations: 🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China

Universal 4SCAR7U Targeting CD7-positive Malignancies

Phase 1

Recruiting

Conditions: T-cell Acute Lymphoblastic Lymphoma
NK Cell Lymphoma
T-cell Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia

Interventions: Biological: Universal CD7-specific CAR gene-engineered T cells

First Posted Date: 2023-08-16

Last Posted Date: 2023-10-12

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 30

Registration Number: NCT05995028

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Universal CAR-T Cells Targeting AML

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Biological: CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells

First Posted Date: 2023-08-16

Last Posted Date: 2023-10-12

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 30

Registration Number: NCT05995041

Locations: 🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China

4SCAR19U T Cells Targeting B Cell Malignancies

Phase 1

Recruiting

Conditions: B Cell Malignancies

Interventions: Biological: Universal CD19-specific CAR gene-engineered T cells

First Posted Date: 2023-08-16

Last Posted Date: 2023-10-12

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 30

Registration Number: NCT05995015

Locations: 🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China

CAR-T Cells Targeting Autoimmune Diseases

Phase 1

Recruiting

Conditions: Autoimmune Diseases

Interventions: Biological: 4SCAR T cells

First Posted Date: 2022-07-15

Last Posted Date: 2022-07-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 30

Registration Number: NCT05459870

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
Guilin Hospital of Chinese Traditional and Western Medicine, Guilin, Guangxi, China

GD2/CD70 Bi-specific CAR-T Cell Therapy

Phase 1

Recruiting

Conditions: Cancer Disease

Interventions: Biological: bi-4SCAR GD2/CD70 T cells

First Posted Date: 2022-06-30

Last Posted Date: 2022-06-30

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 30

Registration Number: NCT05438368

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy